Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05377255
Other study ID # EBS-NAR-001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 28, 2022
Est. completion date May 10, 2022

Study information

Verified date March 2024
Source Emergent BioSolutions
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will be a Phase 1, single-center, open-label, randomized cross-over study to evaluate the PK of a new AP003 device which delivers two sprays of 4 mg naloxone hydrochloride intranasally.


Description:

Based on the intended AP003 product presentation there will be two devices in each carton allowing for administration of a total of 16 mg. This study is designed for subjects to receive naloxone therapy either through the AP003 device or through the currently approved NARCANĀ® nasal spray (4 mg) device (per label), reference therapy. After administration of the therapy patients will be followed by a 48-hour washout period before treatment crossover. Key study parameters include safety and PK. Safety evaluations will include but not limited to complete and system directed physical examinations (including signs of nasal irritation such as erythema, edema, and erosion), administration of a Brief Smell Identification Test (B-SIT), assessments of vital signs, 12 lead electrocardiogram (ECG), continuous cardiac telemetry monitoring (CCT) , clinical laboratory tests (e.g., hematology, chemistry, urinalysis, pregnancy test), and evaluation of adverse events.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date May 10, 2022
Est. primary completion date May 10, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Are able to consent and freely provide informed consent. - Females and males 18-55 years of age, inclusive. - Have a body mass index (BMI) less than or equal to 34.0 kg/m2. - Generally healthy, in the opinion of the Investigator, based on medical history, physical examination, vital signs, screening laboratory assessments and 12-lead ECG evaluation. - If female: 1. Have a negative pregnancy test at Screening (serum pregnancy test) and before dosing at Day -1 (urine pregnancy test) 2. Female subjects of non-childbearing potential must be: - Post-menopausal (spontaneous amenorrhea for at least 12 months prior to dosing) with confirmation by documented FSH levels =40 mIU/mL; or - Surgically sterile (bilateral oophorectomy, bilateral salpingectomy, hysterectomy, or tubal ligation) at least 3 months prior to dosing. 3. Women of childbearing potential who are not planning to be pregnant during the study period and who are using one of the following effective methods of contraception during the study period and for at least 30 days after last study visit: - Simultaneous use of hormonal contraceptive (e.g. oral, patch, depot injection, implant, vaginal ring, intrauterine device) or non-hormonal intrauterine device for at least 4 weeks prior to dosing (must agree to use the same contraceptive throughout the study) and condom for the male partner. - Simultaneous use of diaphragm or cervical cap with spermicide and condom for the male partner, started at least 21 days prior to dosing. Exclusion Criteria: - Subjects planning to become pregnant during the study or currently breastfeeding. - Any acute condition, in the opinion of the Investigator, that is not fully resolved at least 4 weeks prior to baseline. - Subject has a deviated septum, previous rhinoplasty, abnormal nasal anatomy, other nasal symptoms (i.e., blocked and/or runny nose), or other nasal surgeries (i.e., polyp removal) within 1 year, or needs to use another nasal spray product during study. - Subject with current upper respiratory infection (URI) or has had URI within 7 days prior to screening. - Subject has had an episode of epistaxis within 30 days prior screening or has experienced recurrent episodes of epistaxis within 1 year prior to screening. - Subject has used any prescription or nonprescription drugs/supplements with increased risk of bleeding within 28 days or 5 half-lives (whichever is longer) or complementary and alternative medicines within 28 days before the first dose of study drug with exception of oral contraceptives. All other prescription medications, over-the-counter, and natural health products within 14 days or 5 half-lives prior to the first dosing. - Subject is currently participating in another clinical study of an investigational drug or has been dosed with any investigational drug within 30 days or 5 half-lives (whichever is longer) of the compound.

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
16 mg naloxone AP003
4 doses of 4 mg each (total: 16 mg) of naloxone through the AP003 device
8 mg naloxone NARCAN Nasal Spray
2 doses of 4 mg each (total: 8 mg) of the naloxone through the NARCAN Nasal Spray device

Locations

Country Name City State
United States Syneos Health Clinical Research Services Miami Florida

Sponsors (1)

Lead Sponsor Collaborator
Emergent BioSolutions

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean naloxone plasma concentration AP003 dosing periods. The mean naloxone plasma concentration during the two AP003 dosing periods. PK samples taken at various timepoints over the course of Pre-dose and post-dose for 12 hours.
Primary Mean naloxone plasma concentration Narcan dosing periods The mean naloxone plasma concentration during the two Narcan dosing periods. PK samples taken at various timepoints over the course of Pre-dose and post-dose for 12 hours.
Primary Incidence of treatment emergent adverse events (TEAEs), serious adverse events (SAE) Incidence of treatment emergent adverse events (TEAEs), serious adverse events (SAE) by treatment thru End of Study Visit (within 7 days after 2nd dose). Through end of study visit (within 7 days after second dose)
Primary Incidence of abnormal vital signs Incidence of abnormal vital signs (heart rate, blood pressure, and respiration rate) by treatment thru End of Study Visit (within 7 days after 2nd dose). Through end of study visit (within 7 days after second dose)
Primary Incidence of clinically significant ECG Incidence of clinically significant ECG by treatment thru End of Study Visit (within 7 days after 2nd dose). Through end of study visit (within 7 days after second dose)
Primary Incidence of clinical laboratory changes Incidence of clinical laboratory changes by treatment thru End of Study Visit (within 7 days after 2nd dose). Through end of study visit (within 7 days after second dose)
Primary Incidence of adverse events of special interest (AESI) indicating of nasal irritation Incidence of adverse events of special interest (AESI) indicating of nasal irritation (erythema, edema, and erosion) by treatment thru End of Study Visit (within 7 days after 2nd dose). Through end of study visit (within 7 days after second dose)
Primary Incidence of changes in B-SIT assessment Incidence of changes in B-SIT assessment within an AP003 period thru End of Study Visit (within 7 days after 2nd dose). Through end of study visit (within 7 days after second dose)
See also
  Status Clinical Trial Phase
Completed NCT04372238 - The Rhode Island Prescription and Illicit Drug Study N/A
Recruiting NCT03924505 - Preventing Opioid Overdose Mortality in the United States N/A
Completed NCT05093309 - Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone N/A
Completed NCT05219669 - Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens Phase 1
Completed NCT04317053 - Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program Phase 3
Not yet recruiting NCT06466005 - UnityPhilly Response App for Overdose Reversal
Recruiting NCT04815590 - Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
Active, not recruiting NCT05096429 - Preventing Overdose Using Information and Data From the Environment N/A
Suspended NCT05114460 - Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal Phase 2
Recruiting NCT06238128 - Opioid Rapid Response System: Naloxone Training in Communities N/A
Completed NCT02662153 - Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics
Active, not recruiting NCT05944133 - Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD
Recruiting NCT05877118 - Improving Availability of Intranasal Naloxone N/A
Recruiting NCT05072249 - European Cohort Study of the Effectiveness of Take Home Naloxone
Withdrawn NCT05808881 - Clinical Outcomes From Nalmefene Phase 4
Not yet recruiting NCT01622504 - Naloxone Nasal Spray Pharmacokinetic Study Phase 1
Not yet recruiting NCT06429436 - Vending Machine Naloxone Distribution for Your Community (VENDY) Phase 4
Completed NCT05506267 - Development of a Tracheal Sound Sensor
Completed NCT02535494 - Risks and Benefits of Naloxone Prescribing N/A
Not yet recruiting NCT06408714 - Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose Phase 3